Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2
B-cell and T-cell lymphomas and leukemias often have distinct genetic mutations that are diagnostically defining or prognostically significant. A subset of these mutations consists of specific point mutations, which can be evaluated using genetic sequencing approaches or point mutation specific anti...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/11/4/600 |
| id |
doaj-065c902f411e43e7816b5fe5326557da |
|---|---|
| record_format |
Article |
| spelling |
doaj-065c902f411e43e7816b5fe5326557da2021-03-28T00:03:43ZengMDPI AGDiagnostics2075-44182021-03-011160060010.3390/diagnostics11040600Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2Kunwar Singh0Sumanth Gollapudi1Sasha Mittal2Corinn Small3Jyoti Kumar4Robert S. Ohgami5Department of Pathology, Stanford University, Stanford, CA 94063, USADepartment of Pathology, University of California, San Francisco, CA 94143, USADepartment of Pathology, University of California, San Francisco, CA 94143, USADepartment of Pathology, University of California, San Francisco, CA 94143, USADepartment of Pathology, Stanford University, Stanford, CA 94063, USADepartment of Pathology, University of California, San Francisco, CA 94143, USAB-cell and T-cell lymphomas and leukemias often have distinct genetic mutations that are diagnostically defining or prognostically significant. A subset of these mutations consists of specific point mutations, which can be evaluated using genetic sequencing approaches or point mutation specific antibodies. Here, we describe genes harboring point mutations relevant to B-cell and T-cell malignancies and discuss the current availability of these targeted point mutation specific antibodies. We also evaluate the possibility of generating novel antibodies against known point mutations by computationally assessing for chemical and structural features as well as epitope antigenicity of these targets. Our results not only summarize several genetic mutations and identify existing point mutation specific antibodies relevant to hematologic malignancies, but also reveal potential underdeveloped targets which merit further study.https://www.mdpi.com/2075-4418/11/4/600single nucleotide polymorphismshematopathologycancerdiagnosticspoint mutation specific antibodiesprecision medicine |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Kunwar Singh Sumanth Gollapudi Sasha Mittal Corinn Small Jyoti Kumar Robert S. Ohgami |
| spellingShingle |
Kunwar Singh Sumanth Gollapudi Sasha Mittal Corinn Small Jyoti Kumar Robert S. Ohgami Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2 Diagnostics single nucleotide polymorphisms hematopathology cancer diagnostics point mutation specific antibodies precision medicine |
| author_facet |
Kunwar Singh Sumanth Gollapudi Sasha Mittal Corinn Small Jyoti Kumar Robert S. Ohgami |
| author_sort |
Kunwar Singh |
| title |
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2 |
| title_short |
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2 |
| title_full |
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2 |
| title_fullStr |
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2 |
| title_full_unstemmed |
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2 |
| title_sort |
point mutation specific antibodies in b-cell and t-cell lymphomas and leukemias: targeting idh2, kras, braf and other biomarkers rhoa, irf8, myd88, id3, nras, sf3b1 and ezh2 |
| publisher |
MDPI AG |
| series |
Diagnostics |
| issn |
2075-4418 |
| publishDate |
2021-03-01 |
| description |
B-cell and T-cell lymphomas and leukemias often have distinct genetic mutations that are diagnostically defining or prognostically significant. A subset of these mutations consists of specific point mutations, which can be evaluated using genetic sequencing approaches or point mutation specific antibodies. Here, we describe genes harboring point mutations relevant to B-cell and T-cell malignancies and discuss the current availability of these targeted point mutation specific antibodies. We also evaluate the possibility of generating novel antibodies against known point mutations by computationally assessing for chemical and structural features as well as epitope antigenicity of these targets. Our results not only summarize several genetic mutations and identify existing point mutation specific antibodies relevant to hematologic malignancies, but also reveal potential underdeveloped targets which merit further study. |
| topic |
single nucleotide polymorphisms hematopathology cancer diagnostics point mutation specific antibodies precision medicine |
| url |
https://www.mdpi.com/2075-4418/11/4/600 |
| work_keys_str_mv |
AT kunwarsingh pointmutationspecificantibodiesinbcellandtcelllymphomasandleukemiastargetingidh2krasbrafandotherbiomarkersrhoairf8myd88id3nrassf3b1andezh2 AT sumanthgollapudi pointmutationspecificantibodiesinbcellandtcelllymphomasandleukemiastargetingidh2krasbrafandotherbiomarkersrhoairf8myd88id3nrassf3b1andezh2 AT sashamittal pointmutationspecificantibodiesinbcellandtcelllymphomasandleukemiastargetingidh2krasbrafandotherbiomarkersrhoairf8myd88id3nrassf3b1andezh2 AT corinnsmall pointmutationspecificantibodiesinbcellandtcelllymphomasandleukemiastargetingidh2krasbrafandotherbiomarkersrhoairf8myd88id3nrassf3b1andezh2 AT jyotikumar pointmutationspecificantibodiesinbcellandtcelllymphomasandleukemiastargetingidh2krasbrafandotherbiomarkersrhoairf8myd88id3nrassf3b1andezh2 AT robertsohgami pointmutationspecificantibodiesinbcellandtcelllymphomasandleukemiastargetingidh2krasbrafandotherbiomarkersrhoairf8myd88id3nrassf3b1andezh2 |
| _version_ |
1724200557100400640 |